Biognosys AG. (10/5/21). "Press Release: Biognosys Announces the Launch of its Next-Generation Plasma Biomarker Discovery Solution". Schlieren.

	Organisation	Biognosys AG
	Group	Bruker (Group)
	Organisation 2	Society for Immunotherapy of Cancer (SITC)
	Product	biomarker discovery technology
	Product 2	HRM-MS technology (Hyper Reaction Monitoring)
	Person	Serroen, Yves (Biognosys 202109 Head of Marketing)

The new and improved workflow will offer unprecedented depth and quantitative precision, identifying up to 3,000 plasma proteins

Biognosys, a leader in next-generation proteomics solutions for drug discovery and development, today announces the upcoming launch of its next-generation plasma biomarker discovery solution.

The launch will feature a:

• Launch Webinar on November 9th – Plasma Proteomics: The Next Frontier of Biomarker Discovery in the Precision Medicine Era

• Launch Exhibition at the Society for Immunotherapy of Cancer (SITC) Annual Meeting on November 12-14th in Washington, D.C.

The biomarker discovery solution will be offered as a contract research service, designed to help biopharma and academic researchers decode the complexity of biology and unlock true, unbiased discoveries for drug development.

The new and improved workflow will offer unprecedented depth and quantitative precision. The workflow will search the complete plasma proteome to identify up to 3,000 of the most relevant plasma proteins. Measuring on average ten peptides for each identified protein, the research service will provide the deepest ever understanding of the key pathways involved in discovery research.

The workflow can be applied across all biological species and to other biofluids, such as cerebrospinal fluid (CSF) or urine. In addition to the biofluid biomarker discovery service, an improved tissue biomarker discovery service will become available, offering an industry-leading depth of 10,000 proteins.

Both solutions will be based on Biognosys’ proprietary, patented Hyper Reaction Monitoring (HRM™) technology and the latest, optimized LC-MS workflow.

Contact our team to learn more about early access possibilities and pricing.

About Biognosys

Biognosys is a leader in next-generation proteomics, dedicated to transforming life science by inventing and developing cutting-edge proteomics technology and solutions and making them widely available for pharmaceutical and biotechnology researchers and proteomics experts. The Company offers a versatile portfolio of proprietary proteomics services, software, and kits that provide a multi-dimensional view of protein expression, function, and structure in all biological species and sample types. Biognosys’ unique, patented technologies utilize high-resolution mass spectrometry to quantify thousands of proteins across thousands of samples with industry-leading precision, depth, and throughput. Through advanced data analytics, Biognosys translates data into actionable insights for R&D and clinical research. More information at biognosys.com.

Media Contact Biognosys

Yves Serroen
Head of Marketing
Phone +41 (0) 79 571 09 21
[email protected]

Record changed: 2023-06-05

Picture Swiss Biotech Association Global Village 2025 SBD25 Basel 650x200px

More documents for Bruker (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)